Related Experiment Video
Updated: Jan 11, 2026
Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Postoperative Cost-effectiveness of Prophylactic Amino Acid Therapy for Renal Protection: A Modeled Economic
Alayna Carrandi1, Mussab Faggery1, Rosario Losiggio2
1Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Objective:
To assess the cost-effectiveness of intravenous amino acids (AA) versus placebo in decreasing cardiac surgery-associated acute kidney injury (AKI) among adult patients after cardiac surgery.
Design:
Data on resource use and outcomes were obtained from relevant studies reported in a recent meta-analysis. Cost-effectiveness analyses were conducted using a decision tree model to quantify the incremental costs and health outcomes of AA versus placebo.
Setting:
Cost-effectiveness analyses were conducted separately for Australia, the United States, China, Italy, and the United Kingdom using local unit costs.
Participants:
Adult patients after cardiac surgery.
Interventions:
Intravenous AA versus placebo.
Measurements And Main Results:
The cost-effectiveness analyses expressed outcomes in terms of cost per instance of AKI averted with an in-hospital time horizon and from a healthcare payer perspective. The expected total healthcare cost after surgery in patients treated with AA ranged from $1,871 in China to $37,692 in the United States versus $2,055 in China to $40,213 in the United States for the placebo group, with a per patient cost saving ranging from $184 (95% confidence interval [CI], -$331 to -$32) in China to $2,521 (95% CI, -$3,770 to -$1,260) in the United States. AA also resulted in a 5.2% (95% CI, 5.1%-5.3%) absolute risk reduction in AKI. AA was dominant (cost-saving and cost-effective) across all jurisdictions.
Conclusions:
Compared with placebo, AA infusion decreases the occurrence of AKI and is cost-saving. Perioperative AA therapy is a rational approach to patient care that simultaneously protects renal function and decreases healthcare costs.
Related Concept Videos
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:28Chronic Kidney Disease III: Interprofessional Care
01:20Acute Kidney Injury V: Interprofessional Care
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:29Renal Regulation of Acid-Base Balance
In the kidneys, cells within the proximal convoluted tubules (PCT) and the collecting ducts secrete hydrogen ions (H+) into the tubular fluid. Specifically, in the PCT, Na+/H+ antiporters secrete H+ while reabsorbing Na+.
However, the intercalated cells in...
01:22Acute Kidney Injury I: Introduction